Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZYUS Life Sciences ( (TSE:ZYUS) ) has provided an update.
ZYUS Life Sciences has expanded its Phase 2a UTOPIA-1 cancer pain trial by activating two additional clinical sites in Canada, marking a significant milestone in advancing Trichomylin® softgel capsules into later-stage trials. This expansion is expected to enhance participant diversity and accelerate patient enrollment, strengthening the company’s clinical development program and advancing its mission to provide safer, scientifically validated alternatives to opioid-based pain management therapies.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a clinical-stage life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection and obtain regulatory approval for non-opioid-based pharmaceutical solutions, enhancing shareholder value and transforming patient outcomes.
Average Trading Volume: 10,132
Technical Sentiment Signal: Sell
Current Market Cap: C$45.65M
For detailed information about ZYUS stock, go to TipRanks’ Stock Analysis page.